Emetal tablets


  • Active Ingredient: Metoclopramide
  • 10 mg
Buy Now

What is Emetal?

The active ingredient of Emetal brand is metoclopramide. Metoclopramide increases muscle contractions in the upper digestive tract. This speeds up the rate at which the stomach empties into the intestines.

Used for

Emetal is used to treat diseases such as: Gastroparesis, GERD, Lactation Augmentation, Migraine, Nausea/Vomiting, Nausea/Vomiting, Chemotherapy Induced, Nausea/Vomiting, Postoperative, Radiographic Exam, Small Intestine Intubation.

Side Effect

Possible side effects of Emetal include: tic-like or twitching movements; unusual irritability; drowsiness (severe); fast or irregular heartbeat; weakness of the arms and legs; fever; unusual dryness of the mouth; sore throat.

How to Buy Emetal tablets online?

To buy Emetal online - simply click on the "Buy Now" button in the top and follow on to our store. Order and payment takes a few minutes, and all steps are obvious. We do not take a medical prescription and also we have many procedures of payment. Considering each detail of rapid shipping and confidentiality, you may read on the applicable pages on the hyperlinks from the top menu.

Related Medications


Altosec 40mg, 20mg, 10mg


More info


Sanamidol 40mg, 20mg, 10mg


More info


Domstal-RD 10mg


More info


Miliom-D 10mg


More info


Emetal should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Emetal is contraindicated in patients with pheochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phentolamine.

Emetal is contraindicated in patients with known sensitivity or intolerance to the drug. Emetal should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

Emetal may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • drowsiness
  • excessive tiredness
  • weakness
  • headache
  • dizziness
  • diarrhea
  • nausea
  • vomiting
  • breast enlargement or discharge
  • missed menstrual period
  • decreased sexual ability
  • frequent urination
  • inability to control urination

Inactive Ingredients

Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Stearic Acid.

reglan ® tablets (Emetal tablets, USP) 5 mg are green, elliptical-shaped tablets engraved “REGLAN” over “5” on one side and “ANI” on the opposite side.

Each tablet contains:

Emetal base 5 mg (as the monohydrochloride monohydrate)

What other drugs will affect Emetal?

Using Emetal with other drugs that make you drowsy can worsen this effect. Ask your doctor before you take opioid pain medication, a sleeping pill, a muscle relaxer, or medicine for anxiety, depression, or seizures.

Tell your doctor about all your current medicines. Many drugs can affect Emetal, especially:

cyclosporine (Gengraf, Neoral, Sandimmune);

digoxin (digitalis, Lanoxin);

levodopa (Larodopa, Atamet, Parcopa, Sinemet);

tetracycline (Ala-Tet, Brodspec, Panmycin, Sumycin, Tetracap);

atropine (Donnatal, and others), benztropine (Cogentin), dimenhydrinate (Dramamine), methscopolamine (Pamine), or scopolamine (Transderm-Scop);

bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), or solifenacin (Vesicare);

blood pressure medications;

bronchodilators such as ipratroprium (Atrovent) or tiotropium (Spiriva);

irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Anaspaz, Cystospaz, Levsin), or propantheline (Pro-Banthine);

an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate); or

medicines to treat psychiatric disorders, such as chlorpromazine (Thorazine), clozapine (Clozaril, FazaClo), haloperidol (Haldol), olanzapine (Zyprexa, Symbyax), prochlorperazine (Compazine), risperidone (Risperdal), thiothixene (Navane), and others.

This list is not complete and there are many other drugs that can interact with Emetal. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.


Emetal is well absorbed from the gastrointestinal tract in humans and dogs. In humans, bio-availability can be reduced by up to 30% in some patients as a result of first-pass metabolism; this effect is quite variable among individuals. One study suggested that similarly, in dogs, the liver plays an active role in reducing the systemic availability of Emetal after oral administration. In a study of two greyhounds, bioavailability of Emetal after oral administration was about 48%. Bioavailability after intramuscular injection in humans is 74–96%.

The plasma half-life of Emetal in the dog is approximately 90 min. In contrast to humans, in whom glucuronidation and sulfate conjugation are the major metabolic pathways, N-demethylation is more important for Emetal metabolism in dogs.

What is Reglan (Metoclopram >

Reglan is the brand name of the drug Emetal, which is used to treat heartburn and ulcers in people with gastroesophageal reflux disease (GERD).

GERD is a digestive disorder that occurs when stomach acid flows back into the esophagus.

Reglan can also help people with diabetes who have a condition known as gastroparesis (poor emptying of the stomach). It can also be used to treat nausea in certain patients and slowed stomach emptying in those who are recovering from surgery.

This medicine is typically used on a short-term basis (four to 12 weeks).

Reglan is in a class of drugs called prokinetic agents, which work by increasing muscle contractions in the upper digestive tract to speed up movement through the stomach and intestines.

The Food and Drug Administration (FDA) approved Reglan in 1985.

What preparations of Emetal are available?

Tablets: 5 and 10 mg.Syrup: 5 mg/5 ml.Injection: 5 mg/ml

Symptomatic Gastroesophageal Reflux

reglan ® tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy.

The principal effect of Emetal is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of Emetal as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.

Diabetic Gastroparesis (Diabetic Gastric Stasis)

reglan ® tablets (Emetal tablets, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to reglan ® within different time intervals. Significant relief of nausea occurs early and continues to improve over a three-week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more.

Generic Name: Emetal (oral/injection) (MET oh KLOE pra mide)Brand Names: Metozolv ODT, Reglan

Medically reviewed by Drugs.com. Last updated on Apr 8, 2018.

What is Emetal?

Emetal is used to treat nausea, vomiting, and reflux disease in dogs and cats by normalizing their digestive system function. Emetal requires a prescription and is sold per tablet.

For The Relief Of Symptomatic Gastroesophageal Reflux

Administer from 10 mg to 15 mg reglan ® (Emetal hydrochloride, USP) orally up to q.i.d. 30 minutes before each meal and at bedtime, depending upon symptoms being treated and clinical response (see CLINICAL PHARMACOLOGY and INDICATIONS AND USAGE). If symptoms occur only intermittently or at specific times of the day, use of Emetal in single doses up to 20 mg prior to the provoking situation may be preferred rather than continuous treatment. Occasionally, patients (such as elderly patients) who are more sensitive to the therapeutic or adverse effects of Emetal will require only 5 mg per dose.

Experience with esophageal erosions and ulcerations is limited, but healing has thus far been documented in one controlled trial using q.i.d. therapy at 15 mg/dose, and this regimen should be used when lesions are present, so long as it is tolerated (see ADVERSE REACTIONS). Because of the poor correlation between symptoms and endoscopic appearance of the esophagus, therapy directed at esophageal lesions is best guided by endoscopic evaluation.

Therapy longer than 12 weeks has not been evaluated and cannot be recommended.

For the Relief of Symptoms As s ociated with Diabetic Gas tropares is (Diabetic Gas tric Stas is ) Administer 10 mg of Emetal 30 minutes before each meal and at bedtime for two to eight weeks, depending upon response and the likelihood of continued well-being upon drug discontinuation.

The initial route of administration should be determined by the severity of the presenting symptoms. If only the earliest manifestations of diabetic gastric stasis are present, oral administration of reglan ® may be initiated. However, if severe symptoms are present, therapy should begin with Emetal injection (consult labeling of the injection prior to initiating parenteral administration).

Administration of Emetal injection up to 10 days may be required before symptoms subside, at which time oral administration may be instituted. Since diabetic gastric stasis is frequently recurrent, reglan ® therapy should be reinstituted at the earliest manifestation.

Tardive Dyskinesia

Treatment with Emetal can cause tardive dyskinesia (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose. An analysis of utilization patterns showed that about 20% of patients who used Emetal took it for longer than 12 weeks. Treatment with Emetal for longer than the recommended 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD.

Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop Emetal-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose.

Emetal should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after Emetal is withdrawn.

Emetal itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, Emetal should not be used for the symptomatic control of TD.

How should this medication be given:

Emetal is usually given 3 or 4 times a day. Give each dose with plenty of water. Follow your veterinarian's instructions. If you do not understand the directions ask the pharmacist or veterinarian to explain them to you. Store Emetal at room temperature away from moisture and heat. Keep this medication away from children and pets.

© Copyright 2017-2020 - rootsdentclinic.com - We Care About You!